
Galaxy S25 Edge drop test reveals just how resilient (or not) Samsung's super-thin phone really is
Ryan Haines / Android Authority
TL;DR Samsung's thin Galaxy S25 Edge survives its drop test, though not without some damage.
Even with Gorilla Glass Ceramic 2, the front screen is quick to crack, though remains operational.
The rear Victus 2 glass puts up more of a fight, but even it's quickly undone.
Pretty much everything about a smartphone is a compromise. That may sound like a bit of a negative position to be coming from, but it really does make all the sense in the world when you stop to think about it: Bigger screens are easier to see, but more awkward to carry around. Or giant batteries offer the endurance we want, but quickly get heavy. Every time a manufacturer is balancing concerns like these, it's making compromises — and that's fine. More than fine, it's necessary. Today, though, we're taking a close look at the fallout from what's arguably one of the biggest compromises that's been at the forefront of a recent handset's design.
This year, Samsung expanded its flagship Android lineup with the introduction of a new, thinner alternative: the Galaxy S25 Edge. And almost immediately, the phone found itself surrounded by controversy.
With the S25 Edge, Samsung's compromises exist front and center: You get a very thin phone, granted, at the expense of battery life — to say nothing of the very real extra cost associated with its premium price tag. At least, that's the obvious trade-off when you look at the hardware's specs, but thin phones just don't spell less room for a battery. Being thin also makes it a lot more difficult for a phone to be built tough.
Physical resiliency comes easily to big, bulky phones, but more delicate hardware has its work cut out for it. We just saw Zack Nelson put the S25 Edge through some damage tests, and Samsung's phone actually resisted bending admirably well. But how does it handle a few drops?
Over on YouTube, PBKreviews puts the S25 Edge to just such a trial, and the results aren't great. Dropped face-down from about as high as you'd be holding the phone on a call, we immediately get a cracked screen, despite the Corning Gorilla Glass Ceramic 2 protection.
After a couple more drops, this time intentionally trying to get the phone to land on its back, the Victus 2 rear glass also began showing signs of damage. While a slightly lower drop on the phone's edge continues to ding up the frame, the glass damage doesn't really get a whole lot worse, and the screen remains operational throughout. Ultimately, it could have gone a whole lot worse, but considering Samsung's build quality on the mainstream S25 line, this isn't particularly impressive, either.
Do tests like these make you reconsider picking up a Galaxy S25 Edge? Or is that thin build just too sleek to pass up? Make your case for this controversial phone down in the comments.
Got a tip? Talk to us! Email our staff at
Email our staff at news@androidauthority.com . You can stay anonymous or get credit for the info, it's your choice.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Verge
39 minutes ago
- The Verge
Posted Jun 6, 2025 at 3:40 AM EDT 0 Comments / 0 New D Dominic Preston Samsung leaks its own foldable names. And no, they're not exactly surprising. But even so, a Galaxy Store listing for 'Samsung Internet Browser for Fold7 and Flip7,' spotted by GalaxyClub, does give the game away a little, especially since we're not expecting the new phones to launch for at least a month. Of course, that doesn't preclude extra versions, like the Fold Ultra Samsung teased just this week, or its rumored cheaper Flip FE.
Samsung leaks its own foldable names. And no, they're not exactly surprising. But even so, a Galaxy Store listing for 'Samsung Internet Browser for Fold7 and Flip7,' spotted by GalaxyClub, does give the game away a little, especially since we're not expecting the new phones to launch for at least a month. Of course, that doesn't preclude extra versions, like the Fold Ultra Samsung teased just this week, or its rumored cheaper Flip FE.


The Verge
39 minutes ago
- The Verge
Posted Jun 6, 2025 at 3:40 AM EDT
Samsung leaks its own foldable names. And no, they're not exactly surprising. But even so, a Galaxy Store listing for 'Samsung Internet Browser for Fold7 and Flip7,' spotted by GalaxyClub, does give the game away a little, especially since we're not expecting the new phones to launch for at least a month. Of course, that doesn't preclude extra versions, like the Fold Ultra Samsung teased just this week, or its rumored cheaper Flip FE.
Yahoo
an hour ago
- Yahoo
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA). Under the terms of the MSA, OBI grants TegMine rights to utilize OBI's GlycOBI® ADC enabling technologies, powered by EndoSymeOBI® and HYPrOBI®, to identify ADC therapeutics candidates for potential clinical development. If an ADC product candidate(s) is ensued, OBI and TegMine would enter into a formal licensing agreement. 'This strategic collaboration leverages the synergistic strengths of both organizations,' noted Heidi Wang, Ph.D., OBI Pharma's Chief Executive Officer. 'In addition to advancing OBI's compelling ADC products, we are focused on leveraging the innovative ADC enabling technologies, like GlycOBI®, for strategic partnership. We look forward to working closely with TegMine to generate novel ADC candidates to treat patients with unmet medical need.' 'This collaboration reflects the exciting convergence of two innovative platforms,' said Jeff Bernstein, Ph.D., Chief Executive Officer of TegMine Therapeutics. 'OBI's ADC technology is an ideal complement to our efforts to target cancer-specific glycans. Together, we have the opportunity to develop ADCs with unprecedented tumor specificity and therapeutic impact.' About GlycOBI® OBI has developed a unique glycan-based ADC technology (GlycOBI®), which is in a 'Plug and Play' format and compatible with any antibodies, linkers, and payloads in various Drug antibody ratio (DAR). Utilizing OBI's proprietary enzymatic technology (EndoSymeOBI®) and linker technology (HYPrOBITM), GlycOBI® generates site-specific homogenous ADCs with an efficient and scalable process under GMP conditions. The conjugation process of GlycOBI® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI's linker technology has improved conjugation efficiency of the payload, reduced aggregation propensity, which provides advantages on manufacturing ADC products. GlycOBI® has overcome the limitations of traditional ADCs and achieved better antitumor activity and stability in various in vivo animal studies. About OBI Pharma OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop novel cancer therapeutic agents for patients with high unmet medical needs. OBI's primary focus is the development of novel ADCs, including the first-generation cysteine-based TROP2 ADC, OBI-992. Using the company's proprietary ADC enabling technology, GlycOBI®, powered by EndoSymeOBI® and HYPrOBI™; OBI has created its second generation novel ADC pipeline, including monospecific: OBI-902 (TROP2), OBI-904 (Nectin-4), Trastuzumab-ADC (HER2), bi-specifics and dual payload ADCs. To broaden the applicability of the linker technology, HYPrOBI™, OBI further developed a next-generation ThiOBI® platform to enable cysteine-based conjugation. Additionally, OBI's pipeline also includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in tumors. Additional information can be found at GlycOBI®, EndoSymeOBI®, ThiOBI® are registered trademarks of OBI. HYPrOBI™ is a trademark under registration. About TegMine Therapeutics TegMine Therapeutics is a privately held biotechnology company based in San Francisco, California, USA focused on developing next-generation antibody-based therapies that target cancer-associated glycans and glycoproteins. Founded in 2017, TegMine is pioneering a highly selective approach to cancer treatment by exploiting tumor-specific carbohydrate antigens that are largely absent from healthy tissues. These novel targets are being developed into a diverse pipeline of antibody-drug conjugates (ADCs), bispecific antibodies, and cell therapies. TegMine's proprietary TegMiner™ platform enables the discovery and development of therapeutic antibodies against previously inaccessible glycan epitopes, opening new frontiers in oncology for patients with high unmet medical needs. Additional information can be found at included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau. COMPANY CONTACT:Kevin Poulos, Chief Business OfficerOBI Pharma USA, Inc.+1 (619) 537 7698, ext. 102kpoulos@ Jeff Bernstein, CEOTegMine Therapeutics, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data